Insights
Search Results
Client Highlights
11.06.25
Wilson Sonsini Advises Azalea Therapeutics on $82 Million Financing
On November 4, 2025, Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures, and select individual investors. Wilson Sonsini Goodrich & Rosati advised Azalea Therapeutics on the transaction.
Client Highlights
10.28.25
Wilson Sonsini Advises Empirico on License Agreement with GSK
On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
9.17.24
Wilson Sonsini, Attorneys Recognized in 2024 Edition of LMG Life Sciences
On September 17, 2024, LMG Life Sciences recognized several Wilson Sonsini practices and 19 of its attorneys in the 2024 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012.
Client Highlights
12.06.23
Wilson Sonsini Advises Absci on Collaboration with AstraZeneca
On December 4, 2023, Absci, a leader in generative AI antibody discovery, announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. Wilson Sonsini Goodrich & Rosati advised Absci on the transaction.
Client Highlights
3.14.23
Wilson Sonsini Advises Switch on $52 Million Financing and Launch
On March 14, 2023, Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, announced its launch following $52 million of financing. The company’s Series A was co-led by Insight Partners and UCB Ventures. Existing investors Upfront Ventures and BOLD Capital Partners and new investors Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures, and others also participated in the financing. Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch.
Press Releases
12.05.22
Wilson Sonsini Goodrich & Rosati Elects 18 New Partners
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that the firm has elected 18 new partners from its attorney ranks. The promotions will be effective February 1, 2023.
Client Highlights
11.08.22
Wilson Sonsini Advises Insilico Medicine on $1.2 Billion Research Collaboration with Sanofi
On November 8, 2022, Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction.
Client Highlights
4.07.22
Wilson Sonsini Advises IGM Biosciences on Collaboration Agreement
On March 29, 2022, Sanofi and IGM Biosciences, Inc. announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only two target binding sites. Under the terms of the agreement, IGM will receive a $150 million upfront payment and potentially over $6 billion in aggregate development, regulatory, and commercial milestones. A 50:50 profit share in certain major market countries and tiered royalties in the rest of world is planned for oncology targets, and IGM will receive tiered royalties for autoimmune/inflammation targets. Wilson Sonsini Goodrich & Rosati advised IGM on the transaction.
Client Highlights
11.02.21
Firm Advises Synthekine on Collaboration with Merck to Develop Therapeutic Candidates
On November 1, 2021, Synthekine Inc., an engineered cytokine therapeutics company, announced that it has entered into a worldwide research collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The collaboration will leverage Synthekine’s proprietary surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics. Wilson Sonsini Goodrich & Rosati advised Synthekine on the transaction.
Under the terms of the agreement, Synthekine is responsible for initial research efforts in collaboration with Merck, and Merck will have exclusive rights to develop, manufacture, and commercialize surrogate cytokine agonists for up to two cytokine targets. Initially, the collaboration will focus on a target that has the potential to treat autoimmune diseases. Merck will make an upfront payment and will make an additional one-time payment if it designates a second target. Synthekine will be eligible for up to $525 million in development, regulatory, and commercialization milestones, as well as tiered royalties on net sales, for each target. Merck will provide research funding to Synthekine for programs under the collaboration.
The Wilson Sonsini team that advised Synthekine on the transaction included Ken Clark, Jennifer Knapp, Myra Sutanto Shen, Tait Graves, and David Pirko.
For more information, please see Synthekine’s press release.
Under the terms of the agreement, Synthekine is responsible for initial research efforts in collaboration with Merck, and Merck will have exclusive rights to develop, manufacture, and commercialize surrogate cytokine agonists for up to two cytokine targets. Initially, the collaboration will focus on a target that has the potential to treat autoimmune diseases. Merck will make an upfront payment and will make an additional one-time payment if it designates a second target. Synthekine will be eligible for up to $525 million in development, regulatory, and commercialization milestones, as well as tiered royalties on net sales, for each target. Merck will provide research funding to Synthekine for programs under the collaboration.
The Wilson Sonsini team that advised Synthekine on the transaction included Ken Clark, Jennifer Knapp, Myra Sutanto Shen, Tait Graves, and David Pirko.
For more information, please see Synthekine’s press release.
Client Highlights
8.24.21
Wilson Sonsini Advises Tenaya Therapeutics on $207 Million IPO
On August 3, 2021, Tenaya Therapeutics, a biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease, announced the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering were $207.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tenaya. All shares in the offering were offered by Tenaya. The shares began trading on the Nasdaq Global Select Market on July 30, 2021, under the ticker symbol “TNYA.”
Client Highlights
5.20.20
Firm Represents Mammoth in Deal with GlaxoSmithKline to Develop COVID-19 Test Using CRISPR-Based Platform
On May 20, 2020, just weeks after Bay Area-based Mammoth Biosciences announced its proprietary CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, Wilson Sonsini Goodrich & Rosati assisted Mammoth in striking a deal with GlaxoSmithKline Consumer Healthcare to accelerate development of the test in hopes of getting it in the hands of healthcare providers and consumers as soon as possible.